FLT3 and acute myeloid leukemia: Despite initial challenges with the first-generation tyrosine kinase inhibitors (TKIs), which were associated with systemic toxicities, off-target effects and suboptimal target inhibition, there has been recent clinical success, with some TKIs including midostaurin and gilteritinib being clinically approved by the USA Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as either monotherapy or combined with conventional chemotherapy for patients with de novo or relapse/refractory FLT3-ITDMUT AML [11,12,13,14].